HutchMed Announces First Commercial Shipments of Tazverik Across China
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the first commercial shipments of Tazverik (tazemetostat) across...
Epizyme
HutchMed’s Tazverik Receives Conditional Approval from China’s NMPA for Lymphoma Treatment
China-based HutchMed (NASDAQ: HCM, HKG: 0013) has announced receiving conditional marketing approval from the National...